Humacyte, Inc. (HUMA)
(Delayed Data from NSDQ)
$2.28 USD
-0.12 (-5.00%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.27 -0.01 (-0.44%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HUMA 2.28 -0.12(-5.00%)
Will HUMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HUMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HUMA
Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
HUMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
Other News for HUMA
Humacyte (HUMA) Maintains "Buy" Rating with $25 Price Target | HUMA Stock News
Humacyte (HUMA) Secures Symvess Sale to U.S. Military Treatment Facility | HUMA Stock News
Humacyte announces first sale of Symvess to U.S. Military Treatment Facility
Humacyte (HUMA) Shares Surge on First Symvess Sale to U.S. Military Facility